Share
Facebook
Twitter
Whatsapp
Linkedin
Email
Copy link

Pfizer Struggles to Recover as Covid Demand Plummets and Stock Drops

Pfizer reverses $3.5 billion in revenue amid declining demand for Covid products
Pfizer's stock down over 4%, faces skepticism in turning things around
2024/01/30 (Jan 30th, 2024 12:39 pm)
T
SMALL
T
MEDIUM
T
LARGE
Share

Pfizer’s Revenue Challenges

Pfizer, the pharmaceutical giant, has recently experienced significant setbacks in its revenue due to the decline in its Covid business. The company had to reverse approximately $3.5 billion in revenue, which was expected from the return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. This reversal has affected Pfizer’s financial performance and highlighted the challenges it faces in the current market.

Plunge in Covid Business and Financial Impact

As demand for Covid products declined rapidly and the market shifted toward commercial sales, Pfizer’s fourth-quarter revenue plummeted to $14.25 billion, a 41% decrease compared to the same period last year. This drop in revenue has resulted in a net loss of $3.37 billion, or 60 cents per share, for the fourth quarter. In contrast, Pfizer had a net income of $4.99 billion, or 87 cents per share, during the same period the previous year. Excluding certain items, the company reported an earnings per share of 10 cents for the quarter.

Stock Performance and Future Prospects

Pfizer’s stock experienced a significant decline of approximately 40% in 2023 due to the plummeting demand for its Covid products worldwide. The company had to revise its full-year revenue forecast, incur substantial charges related to inventory write-offs, and implement cost-cutting measures. Furthermore, Pfizer’s future in the weight loss drug market also seems uncertain.

BTC/USDT
0
24h Chg. %
0%
7d Chg. %
0
0%
0
Price
0%
7d Chg. %
0%
7d Chg. %
0
0%
Buy
Sell

Investors are eagerly awaiting data on Pfizer’s once-daily weight-loss drug, danuglipron, which is expected to be released in the first half of this year. The success of this drug could potentially help restore investor confidence in Pfizer’s market position.

Pfizer’s recent acquisition of cancer drugmaker Seagen, worth $34 billion, is another move to boost investor confidence and diversify its portfolio. The acquisition was finalized in the fourth quarter of last year, and Pfizer plans to create a new oncology division that includes Seagen in early 2024.

Despite these efforts, Wall Street remains skeptical about Pfizer’s ability to turnaround. The company’s stock has already experienced a decline of over 4% this year, resulting in a market value of approximately $155 billion.

Expert Analysis
Pfizer's Rocky Road to Recovery: Identifying Hidden Gems in the Midst of Declining COVID Demand
David Thompson

Pfizer Struggles to Recover as Covid Demand Plummets and Stock Drops

Pfizer's recent challenges have had a Bearish impact on its stock price and financial performance. With the decline in demand for its Covid products, the company had to reverse $3.5 billion in expected revenue from the return of doses of its Covid drug, Paxlovid, resulting in a significant financial setback.

This decline in Covid business has led to a 41% decrease in Pfizer's fourth-quarter revenue, resulting in a net loss of $3.37 billion. The stock price has also been significantly affected, experiencing a decline of approximately 40% in 2023.

Future Prospects and Market Perception

All eyes are now on Pfizer's once-daily weight-loss drug, danuglipron, expected to be released in the first half of this year. The success of this drug could potentially restore investor confidence in Pfizer's market position.

Pfizer's acquisition of cancer drugmaker Seagen is another move aimed at boosting investor confidence and diversifying its portfolio. However, despite these efforts, Wall Street remains skeptical about Pfizer's ability to turn things around. The company's stock has already experienced a decline of over 4% this year, resulting in a market value of approximately $155 billion.

The overall Bearish sentiment surrounding Pfizer is driven by the sharp decline in Covid business and uncertainty surrounding its weight loss drug and future market performance.

What challenges has Pfizer's revenue faced?
Pfizer's revenue has faced challenges due to the decline in its Covid business, resulting in significant setbacks.
How much revenue did Pfizer reverse due to its Covid drug?
Pfizer reversed approximately $3.5 billion in revenue, which was expected from the return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government.
What was Pfizer's fourth-quarter revenue and how does it compare to the previous year?
Pfizer's fourth-quarter revenue was $14.25 billion, a 41% decrease compared to the same period last year.
What is Pfizer's stock performance and future prospects?
Pfizer's stock has experienced a significant decline of approximately 40% in 2023 due to the plummeting demand for its Covid products. The company's future prospects include the release of its once-daily weight-loss drug and its acquisition of cancer drugmaker Seagen.
What is Pfizer's market value and how has its stock performed this year?
Pfizer's market value is approximately $155 billion. Its stock has already experienced a decline of over 4% this year.

Bitcoin

19,157.7
-13.2
25.65%
13:00:30 - Real-time Data
Related articles
Bitcoin holds steady around $19,000 amid growing signs of institutional adoption
2022/10/11
Bitcoin holds steady around $19,000 amid growing signs of institutional adoption
2022/10/11
Bitcoin holds steady around $19,000 amid growing signs of institutional adoption
2022/10/11